HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir

AIDS

Volumn 15, Issue 6, 2001, Pages 747-751

  Lanier, E Randall ^a   Sturge, Glenn ^b   McClernon, Daniel ^a   Brown, Stephen ^c   Halman, Mark ^d   Sacktor, Ned ^e   McArthur, Justin ^f   Atkinson, Joseph H ^f   Clifford, David ^g   Price, Richard W ^h   Simpson, David ⁱ   Torres, Gabriel ^j   Catalan, Jose ^k   Marder, Karen ^l   Power, Chris ^m   Hall, Colin ⁿ   Romero, Carmen ^o   Brew, Bruce ^p  

^a GLAXOSMITHKLINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c TRP/DAIDS/NIAID/NIH   (United States)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h SAN FRANCISCO GENERAL HOSPITAL   (United States)

ⁱ MOUNT SINAI MEDICAL CENTER   (United States)

^j ST VINCENT S HOSPITAL   (United States)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

^l Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^m UNIVERSITY OF MANITOBA   (Canada)

ⁿ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^o Glaxo Wellcome   (Spain)

^p ST VINCENT S HOSPITAL   (Australia)

more..

Author keywords

Abacavir; Cerebrospinal fluid; Genotype; HIV 1; HIV 1 RNA; Reverse transcriptase

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; COMPLEMENTARY DNA; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PLASMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DNA MUTATIONAL ANALYSIS; DOUBLE-BLIND METHOD; GENOTYPE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 0035853408     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200104130-00010     Document Type: Article

References (7)

1. Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereo-selectivity of antiviral activity
2. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89
3. Abacavir (1592), a second-generation nucleoside HIV reverse transcriptase inhibitor
4. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus
5. Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism
6. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
7. Analysis of possible predictors of response to abacavir (ABC) in antiretroviral-experienced adults; comparison of viral genotype, viral phenotype and patient treatment history